GPT and fatty liver disease: In a stratification analysis according to ALT > 30 U/L, luseogliflozin significantly decreased fatty liver index, NAFLD liver fat score, and hepatic steatosis index after 24 weeks (Figs. 3A, 3B, and 3C).